Health Care [ 9/12 ] | Biotechnology [ 42/73 ]
NASDAQ | Common Stock
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases.
Its lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis.
The company is also developing ARQ-154, a topical ZORYVE foam for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-255, a selective small molecule inhibitor of JAK1 for the treatment of alopecia areata; ARQ-252, a JAK1-selective topical cream in development for hand eczema and vitiligo; and ARQ-234, a CD200R fusion protein for the treatment of atopic dermatitis.
The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019.
Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 6, 25 | -0.13 Increased by +69.05% | -0.17 Increased by +23.53% |
| May 12, 25 | -0.20 Increased by +37.50% | -0.73 Increased by +72.60% |
| Feb 25, 25 | -0.09 Increased by +87.50% | -0.26 Increased by +65.95% |
| Nov 6, 24 | -0.33 Increased by +54.79% | -0.42 Increased by +21.43% |
| Aug 14, 24 | -0.42 Increased by +63.79% | -0.52 Increased by +19.23% |
| May 14, 24 | -0.32 Increased by +75.57% | -0.73 Increased by +56.16% |
| Feb 27, 24 | -0.72 Increased by +38.98% | -0.77 Increased by +6.49% |
| Nov 3, 23 | -0.73 Increased by +61.38% | -0.86 Increased by +15.12% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 25 | 81.50 M Increased by +164.13% | -15.89 M Increased by +69.64% | Decreased by -19.49% Increased by +88.51% |
| Mar 31, 25 | 65.85 M Increased by +32.84% | -25.06 M Increased by +29.17% | Decreased by -38.06% Increased by +46.68% |
| Dec 31, 24 | 71.36 M Increased by +427.58% | -10.79 M Increased by +83.72% | Decreased by -15.12% Increased by +96.92% |
| Sep 30, 24 | 44.76 M Increased by +17.44% | -41.54 M Increased by +7.21% | Decreased by -92.81% Increased by +20.99% |
| Jun 30, 24 | 30.86 M Increased by +494.57% | -52.33 M Increased by +26.28% | Decreased by -169.59% Increased by +87.60% |
| Mar 31, 24 | 49.57 M Increased by +1.68 K% | -35.38 M Increased by +55.63% | Decreased by -71.38% Increased by +97.51% |
| Dec 31, 23 | 13.53 M Increased by +356.81% | -66.28 M Increased by +12.34% | Decreased by -490.05% Increased by +80.81% |
| Sep 30, 23 | 38.11 M Increased by +5.16 K% | -44.77 M Increased by +58.44% | Decreased by -117.47% Increased by +99.21% |